Description: ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic used for the treatment of myelodysplastic syndromes and acute myeloid leukemia, as well as a range of solid tumor indications, including head and neck squamous cell and human epidermal growth factor receptor 2 positive gastric/gastroesophageal junction carcinoma. The company was founded in 2015 and is based in Burlingame, California.
Home Page: www.alxoncology.com
ALXO Technical Analysis
323 Allerton Avenue
South San Francisco,
CA
94080
United States
Phone:
650 466 7125
Officers
| Name | Title |
|---|---|
| Dr. Corey S. Goodman Ph.D. | Independent Exec. Chairman |
| Dr. Jaume Pons Ph.D. | Founder, Pres, CEO & Director |
| Mr. Peter S. Garcia M.B.A. | Chief Financial Officer |
| Ms. Shelly Pinto | VP of Fin. & Chief Accounting Officer |
| Dr. Sophia Randolph M.D., Ph.D. | Chief Medical Officer & Director |
| Dr. Michael Chang Ph.D. | VP of Operations |
| Dr. Chris Byrd J.D., Ph.D. | Gen. Counsel |
| Ms. Jeanne Y. Jew | Chief Bus. Officer |
| Dr. Athanasios Tsiatis M.D. | Sr. VP of Clinical Devel. |
| Dr. Lin Yeong-Liang M.D., M.S. | Sr. VP of Drug Safety & Pharmacovigilance |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.5268 |
| Price-to-Sales TTM: | 5906.2383 |
| IPO Date: | 2020-07-17 |
| Fiscal Year End: | December |
| Full Time Employees: | 55 |